NZ564110A - Formulations for alteration of biophysical properties of mucosal lining - Google Patents

Formulations for alteration of biophysical properties of mucosal lining

Info

Publication number
NZ564110A
NZ564110A NZ564110A NZ56411006A NZ564110A NZ 564110 A NZ564110 A NZ 564110A NZ 564110 A NZ564110 A NZ 564110A NZ 56411006 A NZ56411006 A NZ 56411006A NZ 564110 A NZ564110 A NZ 564110A
Authority
NZ
New Zealand
Prior art keywords
medicament
administration
disease
calcium
infection
Prior art date
Application number
NZ564110A
Other languages
English (en)
Inventor
Wiwik Watanabe
Matthew Thomas
Jeffrey Katstra
Robert Clarke
Original Assignee
Pulmatrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmatrix Inc filed Critical Pulmatrix Inc
Publication of NZ564110A publication Critical patent/NZ564110A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ564110A 2005-05-18 2006-05-18 Formulations for alteration of biophysical properties of mucosal lining NZ564110A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68235605P 2005-05-18 2005-05-18
PCT/US2006/019443 WO2006125153A2 (en) 2005-05-18 2006-05-18 Formulations for alteration of biophysical properties of mucosal lining

Publications (1)

Publication Number Publication Date
NZ564110A true NZ564110A (en) 2010-06-25

Family

ID=37401509

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ564110A NZ564110A (en) 2005-05-18 2006-05-18 Formulations for alteration of biophysical properties of mucosal lining
NZ593475A NZ593475A (en) 2005-05-18 2006-05-18 Calcium salts for reducing exhalation of infectious bioaerosol particles

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ593475A NZ593475A (en) 2005-05-18 2006-05-18 Calcium salts for reducing exhalation of infectious bioaerosol particles

Country Status (13)

Country Link
US (2) US20070053844A1 (enExample)
EP (3) EP1906922A2 (enExample)
JP (2) JP2008540680A (enExample)
KR (1) KR20080018872A (enExample)
CN (2) CN102327285A (enExample)
AU (1) AU2006247077A1 (enExample)
BR (1) BRPI0609924A2 (enExample)
CA (1) CA2608752A1 (enExample)
EA (1) EA016072B1 (enExample)
IL (1) IL187427A0 (enExample)
NO (1) NO20076086L (enExample)
NZ (2) NZ564110A (enExample)
WO (1) WO2006125153A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
DK2315580T3 (da) * 2009-03-26 2012-04-10 Pulmatrix Inc Farmaceutiske formuleringer og fremgangsmåder til behandling af luftvejsinfektioner
PT2410981T (pt) * 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
US20120058198A1 (en) * 2009-03-26 2012-03-08 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
CN102448438A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法
US20120083531A1 (en) * 2009-03-26 2012-04-05 Clarke Robert W Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
CA3086367A1 (en) 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
WO2015017316A2 (en) 2013-08-01 2015-02-05 Abbott Nicholas L Methods and compositions for modifying mucous membranes
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
EP3858440A3 (en) * 2015-11-18 2021-11-03 The Board of Trustees of the Leland Stanford Junior University B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components
JP7334983B2 (ja) * 2018-01-11 2023-08-29 エンフィスィーマ ソリューションズ ベスローテン フェンノートシャップ 肺気腫及びその他の形態のｃｏｐｄの治療のための組成物及び方法
US12337064B2 (en) 2018-09-05 2025-06-24 Sensory Cloud, Inc. Formulations and compositions for ortho- and/or retro-nasal delivery and associated systems, methods and articles
WO2020112063A1 (en) * 2018-11-29 2020-06-04 Yildiz Teknik Universitesi A nasal solution with closed basin natural spring water characteristic and method for obtaining said nasal solution
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
US20230218661A1 (en) * 2022-01-10 2023-07-13 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx
US20220051592A1 (en) * 2020-08-17 2022-02-17 Massachusetts Institute Of Technology Respiratory system simulator systems and methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3229179C2 (de) * 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
US4637815A (en) * 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5571535A (en) * 1990-11-30 1996-11-05 Flowers; Marianne Treatment of topical infections
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5898037A (en) * 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5709202A (en) * 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
TW381088B (en) * 1994-10-14 2000-02-01 Yamanouchi Pharma Co Ltd Azole derivative
AU3705695A (en) * 1994-10-26 1996-05-23 Wellcome Foundation Limited, The Pharmaceutical composition comprising atovaquone
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
BR9909492A (pt) * 1998-04-08 2000-12-12 Lilly Co Eli Liberação pulmonar e nasal de raloxifeno
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
FR2780285B1 (fr) * 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions
US6333051B1 (en) * 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
MXPA01011283A (es) * 1999-05-03 2002-11-04 Battelle Memorial Institute Composiciones par aerosolizacion e inhalacion.
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
AU772096B2 (en) * 2000-03-14 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
JP3481205B2 (ja) * 2000-11-24 2003-12-22 松下電器産業株式会社 インバータ制御用半導体装置および制御方法
WO2002054868A2 (en) * 2000-12-21 2002-07-18 Inhale Therapeutic Syst Pulmonary delivery of polyene antifungal agents
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
AU2003215334A1 (en) * 2002-02-22 2003-09-09 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
EP1531795A4 (en) * 2002-05-02 2011-02-23 Harvard College FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS
US8003080B2 (en) * 2002-05-13 2011-08-23 Alexza Pharmaceuticals, Inc. Delivery of drug amines through an inhalation route
EP1511467A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
US7534781B2 (en) * 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
GB0324897D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (sv) * 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
WO2005094869A1 (en) * 2004-03-30 2005-10-13 Malcolm King Compositions and methods for improved mucus function
CN101090714A (zh) * 2004-07-26 2007-12-19 康泽里克斯公司 通过吸入伊洛前列素和微粒制剂治疗肺动脉高血压症
US20070202051A1 (en) * 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
GB0818476D0 (en) * 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
CN102448438A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法

Also Published As

Publication number Publication date
EP2402001A1 (en) 2012-01-04
WO2006125153A3 (en) 2008-02-28
EA016072B1 (ru) 2012-01-30
AU2006247077A1 (en) 2006-11-23
NO20076086L (no) 2008-02-14
CN101237853A (zh) 2008-08-06
JP2008540680A (ja) 2008-11-20
NZ593475A (en) 2012-12-21
US20150196589A1 (en) 2015-07-16
US20070053844A1 (en) 2007-03-08
BRPI0609924A2 (pt) 2010-05-11
JP2012176990A (ja) 2012-09-13
KR20080018872A (ko) 2008-02-28
EP2308469A1 (en) 2011-04-13
EA200702520A1 (ru) 2008-06-30
CN102327285A (zh) 2012-01-25
IL187427A0 (en) 2011-08-01
CA2608752A1 (en) 2006-11-23
EP1906922A2 (en) 2008-04-09
WO2006125153A2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
US20150196589A1 (en) Formulations for alteration of biophysical properties of mucosal lining
AU2009225363B2 (en) Formulations for decreasing infectivity of pulmonary disease
US8627821B2 (en) Method and device for decreasing contamination
KR20090060348A (ko) 폐 계면활성제 제제 및 점액 클리어런스 촉진 방법
AU2003243191A1 (en) Formulations limiting spread of pulmonary infections
AU2006205108B2 (en) Method and device for decreasing contamination
AU2012258353A1 (en) Formulations for alteration of biophysical properties of mucosal lining
HK1156235A (en) Formulations for alteration of biophysical properties of mucosal lining
HK1167595A (en) Formulations for alteration of biophysical properties of mucosal lining
JP5075638B2 (ja) 汚染を減少させるための方法及び装置
MX2007014468A (en) Formulations for alteration of biophysical properties of mucosal lining
HK1121064A (en) Formulations for alteration of biophysical properties of mucosal lining
HK1165990A (en) Formulations for alteration of biophysical properties of mucosal lining
AU2012202618A1 (en) Formulations for decreasing infectivity of pulmonary disease

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: PULMATRIX INC., US

Free format text: OLD OWNER(S): PULMATRIX INC.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 MAY 2016 BY ANDY BREEDEN

Effective date: 20130529

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAY 2017 BY CPA GLOBAL

Effective date: 20160405

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAY 2018 BY CPA GLOBAL

Effective date: 20170407

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAY 2019 BY CPA GLOBAL

Effective date: 20180405

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAY 2020 BY CPA GLOBAL

Effective date: 20190517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAY 2021 BY CPA GLOBAL

Effective date: 20200403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAY 2022 BY THOMSON REUTERS

Effective date: 20210403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAY 2023 BY THOMSON REUTERS

Effective date: 20220402

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAY 2024 BY THOMSON REUTERS

Effective date: 20230403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAY 2025 BY THOMSON REUTERS

Effective date: 20240401

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAY 2026 BY THOMSON REUTERS

Effective date: 20250402